TL;DR
Get kitchen gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Food Safety News publisher Bill Marler says he is asking the FDA through two citizen petitions to disclose more information about foodborne illness outbreaks, including the companies and locations involved. His argument draws on the agency’s stated commitment to transparency, but the supplied report excerpt does not include the petitions’ full demands or the FDA’s response to them.
Food Safety News publisher Bill Marler says he is asking the Food and Drug Administration to disclose more identifying details in foodborne illness investigations, including company and location information, through two citizen petitions. In an October 2026 Publisher’s Platform column, Marler argues the requests are consistent with the transparency commitments HHS and FDA have already made; the supplied excerpt does not provide the petitions’ full text or an FDA response.
Marler frames the petitions as a request to put federal statements about “radical transparency” into practice in food safety, a concern also raised in a related Publisher’s Platform column. He points to remarks by Health and Human Services Secretary Robert F. Kennedy Jr. and FDA communications that connected transparency to food contents, recalls and outbreak investigations. Marler says the petitions ask for actions the government has already taken or said it supports, but that characterization is his argument, not an independent finding in the supplied material.
The column traces the FDA’s public disclosures, including Executive Incident Summary abstracts for closed outbreak investigations, launched by the agency’s food program on September 24, 2025. Marler calls the abstracts progress but says they can omit details he considers most useful to the public: the companies and locations associated with an outbreak, an issue explored in his discussion of FDA disclosure. He cites reporting that FDA withheld a company name in a mango outbreak summary and that a Listeria summary redacted patient states.
The excerpt says Stop Foodborne Illness petitioned the FDA in February to stop treating company names as confidential. According to Marler, the agency replied that the names were protected by the Trade Secrets Act. He writes that the legal question had since received an answer, but the provided text ends before explaining that answer or setting out the petitions’ specific proposed disclosure rules.
Why Outbreak Identifiers Matter
Company names, product brands and geographic details can help consumers assess whether food they bought may be linked to an investigation. They can also help businesses, public health agencies and people who became ill connect reports that might otherwise appear unrelated. Marler’s central point is that an outbreak summary may provide an account of an investigation while leaving readers unable to identify the products or places it concerns.
That concern has practical stakes, but the column excerpt does not establish that releasing each requested detail would always be legally permissible or that disclosure would prevent illness. Public agencies may need to weigh public health value against privacy, commercial confidentiality and the risk of incorrectly identifying a business before evidence is sufficient. The petitions put those competing interests and the agency’s disclosure standards in focus.
Products Worth Considering
Instant Pot Pro 8-Quart 10-in-1 Electric Pressure Cooker, Black
Instant Pot Duo 6-Quart 7-in-1 Electric Pressure Cooker
Instant Pot InstantChill Plus Ice Cream Maker, 2-Pint
As an affiliate, we earn on qualifying purchases.
How FDA Built Its Transparency Record
The column links the food-safety debate to a broader HHS commitment. Kennedy used the phrase “radical transparency” during his January 29, 2025, Senate confirmation hearing. In a February 18 address to HHS staff, he said transparency was necessary for informed consent. On March 10, HHS directed FDA to explore closing the self-affirmed GRAS pathway and said the agencies wanted Americans to know what was in their food.
FDA later applied the language directly to food safety. A July 9, 2025, letter to food industry leaders said transparency in food safety and nutrition actions was key to reducing foodborne illness and chronic disease. The agency’s September 2025 announcement of outbreak summaries described them as part of that commitment. The column notes that FDA leadership has changed since those statements: Marty Makary resigned in May 2026, and Deputy Commissioner for Food Kyle Diamantas became acting commissioner. It also says President Donald Trump nominated Heidi Overton in August 2026.
“At the FDA, we believe that radical transparency in food safety and nutrition actions is key to reducing foodborne illness and chronic disease.”
— The FDA, in a July 9, 2025, letter to food industry leaders, as quoted by Food Safety News
Petition Details and FDA Response
The supplied source text is incomplete: it cuts off during Marler’s account of an October outbreak and does not reproduce either citizen petition. It is therefore not possible from this material to verify the petitions’ precise requested language, filing dates, legal arguments or requested deadlines. The excerpt also does not include a response from the FDA to the two petitions or establish whether the agency has accepted, rejected or begun reviewing them.
Marler says a legal answer to the Trade Secrets Act issue has emerged, but the provided excerpt does not identify the answer or its source. The legal basis for disclosing particular company or location details, and whether that basis applies across different investigations, remains unclear here. The article should not be read as confirmation that the FDA has agreed to disclose the information.
FDA Review and Disclosure Policy
The next verifiable development would be the publication or review of the two petitions and a formal FDA response. That response could clarify whether the agency will change its outbreak summaries, how it interprets confidentiality rules, and whether it would disclose identifying details only after an investigation closes or under other conditions. No response date is provided in the supplied material.
Until then, the immediate issue is whether the FDA’s existing summaries and recall communications will include more information about companies, brands and affected locations. Any change in policy, as well as the legal reasoning behind it, would determine how much consumers can learn directly from federal outbreak notices.
Key Questions
What is Bill Marler asking the FDA to do?
Marler says two citizen petitions ask the FDA for greater disclosure in food safety matters, especially company and location details in outbreak summaries. The supplied excerpt does not give the petitions’ full wording.
Has the FDA agreed to the petitions?
The source material provided does not include an FDA response to the two petitions. It does not establish that the agency has agreed to change its disclosure practices.
Why does Marler say outbreak summaries need more detail?
He argues that without identifying information, consumers may have difficulty determining which products or businesses are connected to an investigation. He cites summaries that, according to the column, omitted company or patient-location details.
What confidentiality issue does the column raise?
Marler says the FDA told Stop Foodborne Illness that company names were protected by the Trade Secrets Act. The supplied excerpt says he believes the legal question has since been answered but does not explain how.
Source: foodsafetynews.com
